Navigation Links
Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC
Date:4/29/2012

BRAINTREE, Mass., April 29, 2012 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that it has entered into a definitive agreement to acquire the business assets of Hemerus Medical, LLC, a Minnesota-based company that develops innovative technologies for the collection of whole blood, and processing and storage of blood components.  Hemerus has completed Phase 3 clinical trials and has submitted a New Drug Application to the FDA for its unique, patented SOLX® whole blood collection system.

(Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO )

This system's features include a collection set and a storage solution that is believed to considerably extend the quality and effective life of red blood cells.  Hemerus expects FDA approval in calendar year 2012.  The storage solution is the result of research partially funded by the US Army, and invented by Dr. John Hess of the University of Maryland, and the late Dr. Tibor Greenwalt of the University of Cincinnati.  Hemerus holds the exclusive worldwide license to the intellectual property and furthered this research through the development of a whole blood collection set and clinical trials.

Brian Concannon, President and CEO, said: "Hemerus' capabilities complement our planned entry into the whole blood collection market with our differentiated products designed to bring greater efficiency and productivity to whole blood collection and processing.  This is a market that is strategically important with more than 60 million collection procedures annually.  Delivery of a superior blood storage solution offers both medical and economic benefits to our blood center and hospital customers and is important to our leadership position in blood management."

Haemonetics' current broad product
'/>"/>

SOURCE Haemonetics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
2. Haemonetics to Present at J.P. Morgan Healthcare Conference
3. Haemonetics Sets Date for Fourth Quarter Fiscal Year 2011 Earnings Release: May 2, 2011
4. Haemonetics Sets Date for Second Quarter Fiscal Year 2012 Earnings Release: October 31, 2011
5. Haemonetics Reports 8% Revenue Growth for Second Quarter of Fiscal 2012, Adjusted Earnings Per Share of $0.72 and Updates Previously Provided Full Year Earnings Guidance
6. Dave Helsel Joins Haemonetics as Vice President of Global Manufacturing
7. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
8. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
9. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
10. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
11. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014  Lockton Dunning Benefits, the ... Companies, announced the addition of Vice President ... Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... industry experience to the position.  Most recently, she ... at Diplomat Specialty Pharmacy, where she has held ...
(Date:12/24/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... that the Company achieved the Public Notice (Gong ... certificate of TPI,s Qionglai Facility (QLF) from the ... notice period is a significant procedure of GMP ...
(Date:12/24/2014)... and RALEIGH, N.C. , Dec. ... Endo International plc (NASDAQ: ENDP ) (TSX: ... BDSI ) announced today that they have submitted a ... to the U.S. Food and Drug Administration (FDA).  Buprenorphine ... of pain severe enough to require daily, around-the-clock, long-term ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... 2012 /PRNewswire-Asia-FirstCall/ -- ShangPharma Corporation (NYSE: SHP ... pharmaceutical and biotechnology research and development outsourcing company, ... report on Form 20-F for the year ended ... and Exchange Commission (the "SEC"). The annual report ...
... Mindray Medical International Limited (NYSE: MR ), ... worldwide, announced today that it has filed with the ... 20-F that included audited financial statements for the year ... Annual Report on Form 20-F is available on Mindray,s ...
Cached Medicine Technology:ShangPharma Corporation Files 2011 Annual Report on Form 20-F 2Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2
(Date:12/26/2014)... (PRWEB) December 26, 2014 Plugin and template ... TransPack Volume 5 Plugin for Final Cut Pro X. , ... hard light tool to pull off an industry professional look” ... get their hands on TransPack Volume 5, a new level ... is a set of over 50 Final Cut Pro X ...
(Date:12/26/2014)... 2014 Pentec Health, Inc. number fourteen ... of Pennsylvania for 2014. The awards program, created in ... its kind in the country. The program is a ... of Community and Economic Development, the Pennsylvania State Council ... Central Penn Business Journal. , Charlie Wilson, ...
(Date:12/25/2014)... 2014 The microscopy market is ... to reach $5,756.0 million by 2019. Optical microscopy ... The electron microscopes product segment is expected to ... , Rising focus on nanotechnology, technological advancements, and ... microscopy market. , Get Full Copy of Report ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... “Every three months the trends for evening ... dress will be one of the hottest styles in the ... Today, the company releases 26 A-line sweetheart evening dresses, and ... , “We are trying our best to help a ... designs. Along with affordable prices, we provide discounted delivery costs ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... , , , ... of revenue and payment cycle management solutions for the ... Illinois, recently implemented the Emdeon Patient Responsibility Estimator(SM) solution. ... used by BroMenn,s patient access staff to inform patients ...
... , SAN ANTONIO, Aug. 24 Fall 2009 ... in family schedules, which can have a devastating impact on family pets ... season. PurinaCare(R) Pet Health Insurance ( www.purinacare.com ), which is committed to ... urging all pet owners to be aware of the signs of post-summer ...
... , , , ... VRX ) today announced preliminary results from its ... pain associated with postherpetic neuralgia (PHN), a painful and common complication ... did not meet its pre-specified primary efficacy endpoint. Further detailed analyses ...
... WACO, Texas, Aug. 24 Two professors at ... health care plan in their new book Health Care for ... University Press, that does not create a government entitlement program ... care of Americans who currently have coverage. , , ...
... WASHINGTON, Aug. 24 What did all the following businessmen have in common? , ... Merv Griffin (TV Producer) , Tom Witter ... , , They all died from the prostate cancer, ... son, father or grandfather will die from this disease. , , Hank ...
... NANJING, China, Aug. 24 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,(NYSE: ... leading manufacturer and supplier,of branded generic and innovative pharmaceuticals ... University Cancer Center. , Located ... of,China,s renowned cancer research institutions, prominent in pre-clinical and,clinical ...
Cached Medicine News:Health News:Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency 2Health News:Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency 3Health News:Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency 4Health News:Does Your Pet Have Post-Summer Separation Anxiety? 2Health News:Does Your Pet Have Post-Summer Separation Anxiety? 3Health News:Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN) 2Health News:Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN) 3Health News:Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN) 4Health News:Baylor University Economists Call for Different Tack on Health Care Insurance 2Health News:Prostate Cancer Kills - Every 20 Minutes; September Is Prostate Cancer Awareness Month 2Health News:Simcere Announces Strategic Partnership with Sun Yat-Sen University Cancer Center 2
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Severe revision options for the knee and hip...
Severe revision options for the knee and hip...
The Precedent establishes a new generation of revision hip stems....
Medicine Products: